Core Viewpoint - Sanbai Shuo (001300.SZ) announced that its controlling shareholder, Qingdao Haishuo Health Industry Development Co., Ltd. (referred to as "Haishuo Development"), along with its concerted party Ningbo Hechuang Caizhi Investment Partnership (Limited Partnership) (referred to as "Ningbo Hechuang"), collectively holds 129,973,481 shares, accounting for 53.3168% of the company's total share capital [1] Summary by Sections - Haishuo Development and Ningbo Hechuang plan to reduce their holdings by no more than 7,274,426 shares within three months after 15 trading days from the announcement date, which represents 2.9841% of the company's total share capital [1]

Core Viewpoint - Sanbai Shuo (001300.SZ) announced that its controlling shareholder, Qingdao Haishuo Health Industry Development Co., Ltd. ("Haishuo Development"), along with its concerted party Ningbo Hechuang Caizhi Investment Partnership (Limited Partnership) ("Ningbo Hechuang"), holds a total of 129,973,481 shares, representing 53.3168% of the company's total share capital, and 53.6015% when excluding shares in the company's repurchase account [1] Group 1 - Haishuo Development and Ningbo Hechuang plan to reduce their holdings by up to 7,274,426 shares within three months after the announcement, which accounts for 2.9841% of the company's total share capital and 3.0000% when excluding shares in the repurchase account [1]

证券代码：001300 证券简称：三柏硕 公告编号：2026-003 青岛三柏硕健康科技股份有限公司 关于控股股东及其一致行动人减持股份的预披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.减持原因：股东资金需求。 2.减持股份来源：公司首次公开发行前已发行的股份。 3.减持方式：集中竞价方式、大宗交易方式。 4.拟减持股份数量及比例： 青岛三柏硕健康科技股份有限公司（以下简称"公司"）控股股东青岛海硕健 康产业发展有限公司（以下简称"海硕发展"）及其一致行动人宁波和创财智投资 合伙企业（有限合伙）（下称"宁波和创"）合计持有公司股份 129,973,481 股， 占公司总股本的 53.3168%，占剔除公司回购专用账户股份后总股本的 53.6015%。 海硕发展、宁波和创计划自本公告披露之日起 15 个交易日后的 3 个月内，合 计减持公司股份不超过 7,274,426 股，占公司总股本的 2.9841%，占剔除公司回购 专用账户股份后总股本的 3.0000%，其中，以集中竞价方式减持公司股份不超过 2,424,809 股，占公司总股 ...

Group 1 - The controlling shareholder of Sanbai Shuo, Qingdao Haishuo Health Industry Development Co., Ltd., along with its concerted party Ningbo Hechuang Caizhi Investment Partnership, holds approximately 130 million shares, accounting for about 53.32% of the company's total share capital, and about 53.60% when excluding shares in the repurchase account [1] - Haishuo Development and Ningbo Hechuang plan to reduce their holdings by no more than approximately 7.27 million shares within three months after the announcement, representing about 2.98% of the total share capital and 3% when excluding shares in the repurchase account [1] Group 2 - Haili Biological's valuation has decreased by 50% over eight months, with its largest customer being a company that has not yet been established, indicating unusual circumstances surrounding the acquisition [1]

Group 1 - The controlling shareholder, Haishuo Development, and its concerted party, Ningbo Hechuang, collectively hold 130 million shares, accounting for 53.3168% of the total shares, and 53.6015% after excluding shares in the repurchase special account [1] - They plan to reduce their holdings by a maximum of 7.2744 million shares within three months after the disclosure, which represents 2.9841% of the total shares, and 3.0000% after excluding shares in the repurchase special account [1] - The reduction will include a maximum of 2.4248 million shares through centralized bidding, accounting for 0.9947%, and a maximum of 4.8496 million shares through block trading, accounting for 1.9894% [1]

Group 1 - The company Qingdao Sanbaisuo Health Technology Co., Ltd. (referred to as "the company" or "Sanbaisuo") has signed a stock transfer agreement on October 21, 2025, where J.LU INVESTMENTS LLC intends to transfer 13,800,000 shares, representing 5.66% of the company's total share capital, to Zhejiang Qihou Asset Management Co., Ltd. at a price of 13.95 yuan per share, totaling 192,510,000 yuan [1][2] - As of January 12, 2026, the company received a confirmation letter from Shenzhen Stock Exchange regarding the compliance of the stock transfer materials, which is valid for six months, requiring both parties to complete the transfer registration in one go [1][2] - The stock transfer is subject to the completion of procedures at the China Securities Depository and Clearing Corporation Limited Shenzhen Branch, and there is uncertainty regarding the final completion of the transfer [2] Group 2 - The company will closely monitor the progress of the stock transfer and urge both parties to fulfill their information disclosure obligations in accordance with relevant laws and regulations [2] - The confirmation letter from Shenzhen Stock Exchange is a key document related to the stock transfer [3] - The announcement was made by the board of directors of Qingdao Sanbaisuo Health Technology Co., Ltd. on January 12, 2026 [4]

Group 1 - The core point of the announcement is the agreement for J.LU INVESTMENTS LLC to transfer 13,800,000 shares of Qingdao Sanboshou Health Technology Co., Ltd. to Zhejiang Qihou Asset Management Co., Ltd. at a price of 13.95 yuan per share, totaling 192,510,000 yuan, which represents 5.66% of the company's total share capital [1] Group 2 - The Shenzhen Stock Exchange has completed the compliance confirmation for the share transfer, and the confirmation letter is valid for six months, during which the transfer parties must complete the registration of the share transfer [2] Group 3 - The share transfer is subject to the completion of the transfer procedures at the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, and there is uncertainty regarding the final completion of the transfer [3]

Core Viewpoint - J.LU Investments LLC plans to transfer 13,800,000 shares of Sanbai Shuo, representing 5.66% of the total share capital, to Zhejiang Qihou Asset Management Co., which will make Qihou Asset a major shareholder [2] Group 1: Share Transfer Details - J.LU will transfer 13,800,000 unrestricted circulating shares at a price of 13.95 RMB per share, totaling 192,510,000 RMB [2] - The transfer represents 5.66% of the company's total share capital and 5.69% of the total share capital excluding repurchased shares [2] - The transaction is subject to compliance confirmation by the Shenzhen Stock Exchange, which has been completed [2] Group 2: Future Implications - If the transfer is successfully implemented, Qihou Asset will become a shareholder holding more than 5% of the company [2] - The confirmation letter from the Shenzhen Stock Exchange is valid for six months, during which the transfer parties must complete the registration of the share transfer [2]

二、本次协议转让的进展情况 公司于 2026 年 1 月 12 日收到 J.LU 转发的《深圳证券交易所上市公司股份协 议转让确认书》（深证协〔2025〕第 200 号），深圳证券交易所已完成对本次协议 转让股份相关材料的合规确认。确认书有效期为六个月，转让双方需按照确认书载 明的转受让股份数量一次性办理过户登记。 三、其他相关说明 证券代码：001300 证券简称：三柏硕 公告编号：2026-002 青岛三柏硕健康科技股份有限公司 关于持股 5%以上股东协议转让公司部分股份 取得深圳证券交易所合规性确认暨权益变动的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本次协议转让的基本情况 青岛三柏硕健康科技股份有限公司（以下简称"公司"或"三柏硕"）持股 5% 以上股东 J.LU INVESTMENTS LLC（以下简称"J.LU"）与浙江启厚资产管理有限公 司（代表"启厚汇理 3 号证券私募投资基金"）（以下简称"启厚资产"）于 2025 年 10 月 21 日签署了《股票转让合同》，J.LU 拟通过协议转让的方式向启厚资产转 让其持有的公司部分 ...

Group 1 - The core point of the article is that J.LU INVESTMENTS LLC, a shareholder holding more than 5% of the shares, has signed a stock transfer agreement with Qihou Asset to transfer 13.8 million shares, representing 5.66% of the total share capital, at a price of 13.95 yuan per share, totaling 193 million yuan [1] - The Shenzhen Stock Exchange has completed compliance confirmation of the relevant materials for this stock transfer agreement on January 12, 2026 [1] - The transfer is still subject to the completion of transfer procedures, and there is uncertainty regarding whether it can be completed [1]